Biopharmx Corp (NYSEAMERICAN:BPMX) saw unusually-high trading volume on Tuesday . Approximately 31,736,428 shares were traded during mid-day trading, an increase of 287% from the previous session’s volume of 8,194,271 shares.The stock last traded at $0.22 and had previously closed at $0.16.

Separately, Maxim Group reiterated a “buy” rating and set a $1.50 price objective on shares of Biopharmx in a research report on Friday, June 8th.

Biopharmx (NYSEAMERICAN:BPMX) last posted its quarterly earnings data on Thursday, August 30th. The biotechnology company reported ($0.02) EPS for the quarter, meeting analysts’ consensus estimates of ($0.02). The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.02 million.


BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC).

Featured Story: Trading Strategy Methods and Types

Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with's FREE daily email newsletter.